Want to see JP:4598 full AI Analyst Report?
Top Page
Delta-Fly Pharma, Inc.
(4598)
Select Model
Select Model
Rating:40Underperform
Price Target:
¥100.00
▼(-3.85% Downside)
Action:Downgraded
Date:07/24/26
Overall score is dragged down primarily by very weak financial performance (zero revenue in recent years, persistent large losses, heavy cash burn, and sharply eroded equity/assets). Technicals add pressure with a clear downtrend and negative momentum signals. Valuation offers limited support due to a negative P/E and no provided dividend yield.
Positive Factors
No debt
Absence of debt removes recurring interest and principal obligations, lowering near-term default risk and preserving financial flexibility. For a development-stage biotech, no leverage makes it easier to prioritize R&D or seek equity/partner funding without debt covenants constraining programs.
Negative Factors
Zero revenue since FY2023
Sustained absence of revenue removes an internal funding source and forces reliance on external financing, partnerships, or dilutive equity. Over the medium term, this increases execution risk for development programs and heightens funding and dilution pressures if capital markets are constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
No debt
Absence of debt removes recurring interest and principal obligations, lowering near-term default risk and preserving financial flexibility. For a development-stage biotech, no leverage makes it easier to prioritize R&D or seek equity/partner funding without debt covenants constraining programs.
Read all positive factors
Delta-Fly Pharma, Inc. (4598) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥1.52B
Dividend YieldN/A
Average Volume (3M)379.72K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue GrowthN/A
EPS Growth20.94%
CountryJP
Employees12
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-140.45
Shares Outstanding14,305,000
10 Day Avg. Volume693,770
30 Day Avg. Volume379,723
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)66.43
Price to Sales (P/S)0.00
P/FCF Ratio-1.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Delta-Fly Pharma, Inc. Business Overview & Revenue Model
Delta-Fly Pharma, Inc. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 300.00M |
| Gross Profit | -1.44M | -1.59M | -1.51M | -1.63M | 300.00M |
| EBITDA | -1.60B | -1.71B | -1.40B | -1.31B | -959.79M |
| Net Income | -1.63B | -1.72B | -1.43B | -1.33B | -967.30M |
Balance Sheet | |||||
| Total Assets | 246.67M | 434.33M | 1.47B | 906.82M | 1.32B |
| Cash, Cash Equivalents and Short-Term Investments | 145.45M | 338.83M | 1.42B | 844.34M | 1.27B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 212.69M | 156.54M | 241.50M | 115.62M | 91.19M |
| Stockholders Equity | 33.98M | 277.80M | 1.23B | 791.20M | 1.23B |
Cash Flow | |||||
| Free Cash Flow | -1.56B | -1.83B | -1.28B | -1.30B | -940.40M |
| Operating Cash Flow | -1.56B | -1.83B | -1.28B | -1.30B | -940.40M |
| Investing Cash Flow | 0.00 | -206.00K | 207.00K | -326.00K | 0.00 |
| Financing Cash Flow | 1.36B | 756.70M | 1.85B | 882.62M | 119.86M |
Delta-Fly Pharma, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | ¥4.47B | -3.42 | ― | ― | 1135.58% | 2.37% | |
48 Neutral | ¥19.94B | -3.55 | -156.47% | ― | 35.28% | 90.12% | |
47 Neutral | ¥95.17B | -59.13 | ― | ― | 1662.38% | 42.86% | |
41 Neutral | ¥133.92B | -36.70 | -6.88% | ― | 0.62% | 27.66% | |
41 Neutral | ¥81.42B | -24.87 | -44.85% | ― | ― | 31.36% | |
40 Underperform | ¥1.52B | -0.78 | ― | ― | ― | 20.94% |
* General Sector Average
JP:4598
Delta-Fly Pharma, Inc.
106.00
-544.00
-83.69%
JP:4563
AnGes
50.00
-32.00
-39.02%
JP:4587
Peptidream
1,031.50
-499.00
-32.60%
JP:4592
SanBio Co
1,043.00
-1,617.00
-60.79%
JP:4588
Oncolys BioPharma, Inc.
3,250.00
2,511.00
339.78%
JP:4591
Ribomic, Inc.
79.00
-29.00
-26.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.